Skye Bioscience Inc.’s Post

As September comes to an end, let’s revisit some of our favorite moments. Earlier this month, Gift of Life Biologics participated in #AdvancedTherapiesEurope in Portugal, where we had the opportunity to connect with leaders in the industry. 🎤The standout moment of the event occurred when our CEO, Eric Strati, Pharm.D., took the stage alongside Cellex Cell Professionals 🫱🏼🫲🏻Together, they shared valuable insights on fostering international collaborations to support the development of donor-derived #celltherapy. What’s your September highlight? Share it below! ⬇️ #GeneTherapy #BloodCancers #LeadersInCellTherapy

Excited for Interphex to explore the newest in pharma and biotech innovation! Who else is joining, and which companies or sessions are on your must-see list? #Interphex #Pharmaceuticals #Biotech #Innovation #DigitalTransformation #HealthcareTechnology #Automation #Industry4_0 #PharmaIndustry #Biotechnology

7th International Conference on Drug Discovery and Lead Optimization, San Francisco, 1-3 November.   Have a chat with Benedetta Montagnini, our Head of Business Development USA & Pacific, and don’t miss her talk: 📅 2nd November at 17:40 💫Power Your Early-Stage Drug Discovery Projects: Innovation in Assays, High-Throughput Screening, Hit-to-Lead and Beyond.   Benedetta will give an overview of our early-stage innovative drug discovery services and explain how we can help you advance your project. Stay tuned!   #drugdiscovery #leadoptimization #conference 

Two weeks to go until our webinar, where Hilary Beck (Eikon Therapeutics), Dean Phillips (Novartis Institute For Biomedical Research) and Susanne Wright (Apollo Therapeutics) will be sharing their advice and experience on running successful drug discovery teams. Have you registered yet? 👉 https://lnkd.in/e8pA3JcW Whether stepping into your first position in a drug discovery team, or an established leader interested in developing and improving your team's strategies, this webinar is for you. #DrugDiscovery #MedicinalChemistry #ScienceCareers #Leadership #Collaboration #Innovation

News on the collaboration between #Cytiva and #Rentschler: Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/dskqmumK #CDMO #viralvectors #genomicmedicine #genetherapy

#Article: It’s not all about patents and products. It’s people who drive innovation and inspiration in the pharma industry, helping bring ground breaking new medicines to patients in need.  The Medicine Maker invited its audience to throw the spotlight on their inspiring colleagues, peers, leaders, and mentors by submitting nominations for The Medicine Maker’s annual Power List. Here, 30 incredible players making waves in #smallmolecule, #biopharmaceutical, and #advancedmedicine drug development. In an age of political polarity, ongoing and emerging challenges to human health, conflict, and huge shifts in the ways we work, The Medicine Makers Power Listers continue to roll with the world’s punches, using their hard-won capital to generate positivity, inspiration, and innovation. Featuring #SmallMolecules Prof Marc Brown PhD CChem FRSC, Co-founder, MedPharm Matthew Clark, President and CSO, X-Chem J. Jean Cui, Scientific Founder, President, and CEO, BlossomHill Therapeutics Edward Hæggström, CEO, Nanoform Raquel Izumi, COO, President, and Founder, Vincerx Pharma Jerry McMahon, CEO, Storm Therapeutics Anders Nykjær Chief Scientific Officer, Vesper Bio Anne Phelan, CSO, BenevolentAI Mike Riley, CEO, Veranova Beatrice S.etnik, CSO, Altasciences #Biopharmaceuticals Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre Akintunde (Tunde) Bello, MSc, PhD, Snr VP, Head of Clinical Pharmacology, Pharmacometrics, and Bioanalysis, Bristol Myers Squibb Piers Ingram, CEO of Hummingbird Bioscience Mahesh Karande, President and CEO, Omega Therapeutics Seth Lederman, CEO, Tonix Pharmaceuticals Hanns-Christian Mahler, CEO, ten23 health Jane Osbourn OBE, CSO, Alchemab Therapeutics Mike Rea, CEO, IDEA Pharmaceuticals Aliasger Salem, Ass VP for Research, Bighley Chair and Professor of Pharmaceutical Sciences, University of Iowa Paul Peter Tak, MD PhD FMedSci, President and CEO, Candel Therapeutics #AdvancedMedicines Jeffrey Bluestone, CEO and Founder, Sonoma Bio Jason Bock, CEO, CTMC Teresa Foy, Snr VP, Cancer Immunology and Cell Therapy, Thematic Research Center, Bristol Myers Squibb Fabian Gerlinghaus, CEO and Co-Founder, Cellares Audrey Greenberg, CBO and Co-Founder, Center for Breakthrough Medicines, SK pharmteco Reshma Kewalramani, MD FASN, President and CEO, Vertex Pharmaceuticals Michael May, CEO and President, Centre for Commercialization of Regenerative Medicine Sheila Ann Mikhail, Co-founder, Asklepios BioPharmaceutical (AskBio) Phil Vanek, CTO and Partner, Gamma Biosciences Stella K. Vnook, CEO, Likarda Read about The Medicine Makers Power Listers 👇🏼 https://lnkd.in/eGa2xmAe

𝗧𝘂𝗿𝗻 𝗮𝗿𝗼𝘂𝗻𝗱 𝗰𝗮𝘀𝗲 Is there a glimmer of hope for biotech stocks? It seems like it, particularly for biotech companies with an approved product that has been brought to market. Furthermore, it helps a great deal when sales are picking up and the company communicates strength in meeting the expense side from revenue and cash, rather than from another share issue. Is that what we see in Heron Therapeutics? I believe it is. Sales, revenue, and guidance came out strong yesterday at the third-quarter presentation, especially the guidance from Craig Collard. Those of you who have been in the biotech investing game for a long time will remember the CEO, Craig Collard. At the time, both Novo Nordisk and H. Lundbeck were substantial shareholders in Lifecycle Pharma, which was renamed Veloxis in 2011. Craig Collard became the CEO who made the necessary adjustments and eventually executed the sale of the entire company. Lars Fetterlein, Founder and CEO of Advice Capital A/S 📍 Olfert Fischers Gade 8 1311 København K 📞 45 39 30 60 80 🖥 www.advicecapital.dk

As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf

🌟 Exciting News! 🌟 We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!